Company: AGIO
Filing Date: 2025-07-31
Form Type: 10-Q
Source: 0001439222-25-000089
Chunk: 112

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-07-31
Form: 10-Q
Item: Part I, Item 1
Chunk 112
---
Item 1.        Financial Statements (Unaudited)

AGIOS PHARMACEUTICALS, INC.

Condensed Consolidated Balance Sheets 

(Unaudited)(In thousands, except share and per share data)June 30,2025December 31,2024AssetsCurrent assets:Cash and cash equivalents$80,871 $76,247 Marketable securities858,066 817,463 Accounts receivable, net4,986 4,109 Inventory 30,848 27,616 Prepaid expenses and other current assets44,693 40,165 Total current assets1,019,464 965,600 Marketable securities400,467 638,321 Operating lease assets36,785 42,879 Property and equipment, net10,579 11,675 Other non-current assets3,942 4,724 Total assets$1,471,237 $1,663,199 Liabilities and stockholders’ equityCurrent liabilities:Accounts payable$17,532 $16,643 Accrued expenses35,289 46,861 Income taxes payable— 871 Operating lease liabilities17,589 16,781 Total current liabilities70,410 81,156 Operating lease liabilities, net of current portion31,171 40,207 Other non-current liabilities101 880 Total liabilities101,682 122,243 Stockholders’ equity:Preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued or outstanding at June 30, 2025 and December 31, 2024— — Common stock, $0.001 par value; 125,000,000 shares authorized; 74,254,956 shares issued and 58,038,545 shares outstanding at June 30, 2025, and 73,372,696 shares issued and 57,156,285 shares outstanding at December 31, 202474 73 Additional paid-in capital2,521,545 2,493,811 Accumulated other comprehensive income (loss)655 (1,518)Treasury stock, at cost (16,216,411 shares at June 30, 2025 and December 31, 2024)(802,486)(802,486)Accumulated deficit(350,233)(148,924)Total stockholders’ equity1,369,